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THE INFLUENCE 
OF LEUKOCYTE 
FILTRATION DURING 
CARDIOPULMONARY 
BYPASS ON 
POSTOPERATIVE 
LUNG FUNCTION 
A clinical study 
The accumulation of activated leukocytes in the pulmonary circulation plays an 
important role in the pathogenesis of lung dysfunction associated with cardiopul- 
monary bypass. Animal studies have demonstrated that the elimination of leuko- 
cytes from the circulation reduces postoperative lung injury and improves postop- 
erative pulmonary function. We conducted a prospective randomized clinical study 
to evaluate whether postoperative lung function could be improved by use of a 
leukocyte filter during cardiopulmonary bypass. Elective coronary artery bypass 
grafting was done with a leukocyte-depleting arterial blood filter incorporated in the 
extracorporeal circuit (14 patients, leukocyte filter group) or without the filter (18 
patients, control group). Blood samples collected at intervals before, during, and 
after operation were used for analysis of blood cell counts, elastase concentrations, 
and arterial blood gases. The use of the leukocyte filter caused no significant 
reduction in leukocyte count (p = 0.86). There were no differences in postoperative 
lung function between the groups, as assessed through (1) oxygenation index (290 
for leukocyte filter group compared with 329 for control group, 95% confidence 
interval, 286 to 372,p = 0.21), (2) pulmonary vascular resistance (p = 0.10), and (3) 
intubation time (16.6 hours for leukocyte filter group versus 15.7 hours for control 
group, 95% confidence interval, 12.1 to 19.1 hours, p = 0.72). The levels of neutrophil 
elastase were significantly higher at the end of cardiopulmonary bypass in the 
leukocyte filter group (460 pg/L in leukocyte filter group versus 230 pg/L in control 
group, 95% confidence interval, 101 to 359 pg/L, p = 0.003). We conclude that the 
clinical use of the present form of leukocyte-depleting filter did not improve any of 
the postoperative lung function parameters analyzed in this study. (J THORAC 
CARDIOVASC SURG 1995;109:1138-45) 
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p ulmonary dysfunction after cardiopulmonary by-
pass remains an important clinical problem de- 
spite refinements in techniques of extracorporeal 
circulation and improvements in postoperative in- 
tensive care. 
The pathogenesis of postoperative lung injury 
consists of several steps. The initial step is a com- 
plement activation and release of inflammatory me- 
diators as a result of blood exposure to the surface 
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of the cardiopulmonary bypass circuit.l-5 This causes 
the up-regulation of leukocyte adhesive receptors 
CDllb/CD18 (known as Mac-1 or CR3). 6 Further- 
more, the inflammatory c tokines induce the synthe- 
sis of ligand intercellular dhesion molecules on the 
endothelial cells, which leads to enhanced adhesive- 
ness of endothelium for neutrophils. 7 In the phase 
of lung reperfusion at the termination of cardiopul- 
monary bypass, neutrophils adhere to the endothe- 
lial surface of the pulmonary circulation creating a
microenvironment that permits high concentration 
of toxic agents (such as elastase and oxygen radicals) 
released by activated neutrophils?' 9 
Although the experimental studies showed that 
elimination of leukocytes by means of leukocyte 
depletion could interrupt he sequence of these 
events and reduce the postoperative pulmonary 
injury, no clinical data support these observa- 
tions. ~0-12 
The purpose of this clinical study was to deter- 
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mine whether mechanical filtration of leukocytes 
during cardiopulmonary bypass improves the post- 
operative pulmonary function in human beings. 
Patients and methods 
Enrollment of patients. We enrolled 32 male patients 
in the study between September 1992 and March 1993. All 
patients underwent elective coronary artery bypass graft- 
ing. The criteria for eligibility included normal preopera- 
tive pulmonary function, absence of chronic or acute 
pulmonary disease, absence of cardiac valvular disease, 
absence of congenital heart disease or pulmonary hyper- 
tension, and age less than 75 years. There was no signifi- 
cant difference between the groups regarding age (57 + 8 
years for leukocyte-depleted group; 62 -+ 6 years for 
control group, p = 0.07) or preoperative heart ejection 
fraction (64% -+ 12% for leukocyte-depleted group; 
62% _+ 8% for control group, p = 0.63). 
Informed consent was obtained from all patients. The 
study was approved by the institutional ethical committee. 
Study design. We randomly assigned the participating 
patients to receive a leukocyte filter or to undergo an 
operation using the standard cardiopulmonary bypass 
circuit. A randomization scheme with permuted blocks 
design and additional stratification according to the sur- 
geon was used. Leukocyte filtration during cardiopulmo- 
nary bypass was done for 14 patients, and 18 patients 
comprised the control group. 
The patients' pulmonary and hemodynamic parameters 
were monitored after operation. These determinations 
included arterial blood pressure, central venous blood 
pressure, pulmonary artery pressure, pulmonary capillary 
wedge pressure, cardiac output, body temperature, arte- 
rial blood gases, and oxygen saturation of arterial and 
venous blood. Furthermore, blood cell count analyses and 
measurements of elastase-al-antiprotease complex were 
done. 
Anesthesia, operation, and conduct of bypass. Identical 
anesthetic (flunitrazepam, fentanyl, pancuronium) and 
monitoring techniques (electrocardiogram, central venous 
and arterial catheter, pulmonary artery catheter, urinary 
catheter, and temperature probes) were used in both 
groups of patients. No patient received steroids before or 
during the operation. 
The cardiopulmonary b pass circuit used in all patients 
was composed of a disposable membrane oxygenator 
(Dideco, Mirandola, Italy) and St6ckert roller pumps 
(St6ckert, Munich, Germany) primed with crystalloid 
solution containing 2 million KIU of aprotinin (Trasylol, 
Bayer, Leverkusen, Germany). The leukocyte-depleting 
arterial blood filter for extracorporeal service (Leuko- 
Guard-6, Pall Biomedical Products Corp., East Hills, 
N.Y.) was incorporated instead of a standard arterial filter 
in circuits of 14 patients. 
After median sternotomy and heparinization (300 
IU/kg body weight, Liquemin, F. Hoffmann-La Roche & 
Co., Basel, Switzerland), standard cannulation techniques 
of the ascending aorta and the right atrium were used to 
complete the cardiopulmonary b pass. After the institu- 
tion of cardiopulmonary b pass all patients were cooled to 
26 ° to 28 ° C (blood temperature). Nonpulsatile pump flow 
was adjusted to 1.7 to 1.8 L/min per square meter during 
hypothermia. The mean systemic pressure was maintained 
between 40 and 60 mm Hg. Heparin was added to 
maintain an activated clotting time of more than 480 
seconds during bypass (Medtronic HemoTec, Inc., Engle- 
wood, Colo.). During cardiopulmonary b pass lung venti- 
lation was discontinued; ventilation was subsequently re- 
sumed at the end of the period of aortic crossclamping. 
The management of myocardial protection was identi- 
cal in both groups. Cold intermittent blood cardioplegia 
resulting from mixing blood with high potassium car- 
dioplegic solution was administered in an antegrade fash- 
ion into the aortic root or in a retrograde fashion via the 
coronary sinus, or by both methods. 
After operation all patients received mechanical venti- 
lation of the lungs. Pain was controlled with nicomorphine 
(0.5 mg/10 kg) on the request of the patient. No sedatives 
were given. Continuous infusions of vasodilators (nitro- 
glycerin, phentolamine, nifedipine) were used when nec- 
essary to keep the mean arterial pressure between 60 and 
80 mm Hg. As soon as the rectal temperature reached 
36 ° C, attempts to wean the patient from the ventilator 
were initiated. The criteria for extubation of the trachea 
were adequate spontaneous ventilation, cooperation of 
the patient, stable hemodynamics, and absence of signif- 
icant blood loss. 
Hemodynamic measurements and analysis of blood 
samples. Bolus thermodilution measurements of cardiac 
output and calculations of standard hemodynamic param- 
eters were made before cardiopulmonary b pass, after 
closure of the sternum, 3 and 9 hours after the end of 
cardiopulmonary b pass, and on the morning of the first 
postoperative day. 
Intraoperative and postoperative blood samples for 
blood cell counts and elastase determination were col- 
lected the day before operation (baseline), before cardio-. 
pulmonary bypass, during cardiopulmonary bypass (15 
and 30 minutes), and at the end of cardiopulmonary 
bypass. Postoperative samples were obtained 3 and 9 
hours after the end of cardiopulmonary b pass and on the 
first, second, and third days. Blood cell counts were 
determined on samples containing ethylenediaminetet., 
raacetic acid with use of a Technikon H 1 counter (Terry 
Town, N.Y.). 
Blood for elastase determination was immediately cen- 
trifuged (1600 rpm for 10 minutes) and plasma samples 
frozen until the assay was done. Elastase bound to the 
%-protease inhibitor was determined by an enzyme- 
linked immunosorbent assay (PMN Elastase IMAC, 
Merck Diagnostica, Darmstadt, Germany). 
Separate blood samples for arterial blood gas analysis 
(Automatic Blood Gas System, AVL Medical Instruments 
AG, Schaffhausen, Switzerland) were obtained before the 
operation, after the closure of the sternum, and at 2, 4, 7, 
10, 13, 16, 19, and 22 hours after the operation. 
Statistical analysis. All values are expressed as mean 
plus or minus the standard error. Confidence intervals 
were calculated for the control group. 
Differences in clinical characteristics among the groups 
were assessed with the unpaired t test or Mann-Whitney 
test according to the distribution of the data. Serial 
measurements of blood cell counts and pulmonary vascu- 
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Table I. Operative data 
Group 
Leukocyte p 
filter Control Values 
CPB duration 82 -+ 9 88 + 8 0.67 
(rain) 
Aortic crossclamp 50 -+ 10 53 _+ 6 0.26 
time (rain) 
No. of performed 3.3 -+ 0.4 4.2 + 0.4 0.07 
anastomoses 
CPB, Cardiopulmonary b pass. 
lar resistance were analyzed with analysis of variance 
repeated measures. An unpaired two-tailed t test cor- 
rected with the Bonferroni method was used in analysis of 
differences incell counts between the groups at particular 
time points. The two-step method for serial measurements 
described by Matthews and associates 13was used for 
comparison of oxygenation i dex values in both groups. 
An unpaired t test was used to analyze differences be- 
tween postoperative infusion rates of phentolamine and 
nitroglycerine. Simple regression was used to analyze the 
influence of elastase levels on oxygenation i dex. Differ- 
ences were considered statistically significant at a proba- 
bility level of p < 0.05. Data were analyzed with the 
StatView 4.0 software (Abacus Concepts, Inc., Berkeley, 
Calif.) on a Macintosh IIvx computer (Apple Computer, 
Cupertino, Calif.). 
Results 
There was no statistically significant difference be- 
tween groups considering duration of cardiopulmo- 
nary bypass, aortic crossclamp time, or number of 
coronary artery anastomoses performed (Table I). 
Blood cell counts. All values were corrected for 
hemodilution according to hematocrit changes. 
A slight decrease in the total leukocyte count 
during cardiopulmonary bypass was followed by 
leukocytosis in the early and late periods after 
bypass (7.0 + 0.4 × 109/L before bypass versus 
14.9 ± 1.3 x 109/L after bypass for the leukocyte 
filter group;/) < 0.001, and 7.1 ± 0.6 x 109/L before 
bypass versus 14.8 ± 1.1 × 109/L after bypass for the 
control group;/) < 0.001, Fig. 1). The use of the 
leukocyte-depleting filter during cardiopulmonary 
bypass did not cause significant reduction in circu- 
lating leukocytes at any time during or after filtra- 
tion. The analysis of the time course of total leuko- 
cyte count did not reveal any significant difference 
between the groups (p = 0.86). 
The analysis of the peripheral neutrophil counts 
revealed a pattern similar to those described by 
leukocytes (Fig. 2). After cardiopulmonary b pass, 
the number of neutrophils increased significantly 
compared with numbers before bypass (3.7 ± 0.3 × 
109/L before bypass versus 11.8 ± 1.1 × 109/L after 
bypass for the leukocyte filter group;p < 0.001, and 3.6 
± 0.28 × 109/L before bypass versus 12.3 ± 1.0 × 
109/L after bypass for the control group, p < 0.001). 
There was no statistical difference between the groups 
considering neutrophil dynamics (p = 0.94). 
The lymphocyte counts (Fig. 3) showed a slight 
decline after the beginning of cardiopulmonary b - 
pass without he rebound effect in the period after 
bypass, which was observed by neutrophil count. On 
the contrary, there was a sharp and significant 
decline of the lymphocyte count 9 hours after the 
end of cardiopulmonary b pass (baseline value of 
2.20 ± 0.17 × 109/L versus 0.73 + 0.06 × 109/L 9 
hours after cardiopulmonary b pass for the leuko- 
cyte filter group, p < 0.001; baseline count of 1.68 _ 
0.12 × 109/L versus 0.86 + 0.15 x 109/L 9 hours 
after cardiopulmonary b pass for the control group, 
p < 0.001). There was no significant difference in the 
lymphocyte counts between the groups during the 
observed period (p = 0.15). 
Elastase levels. The plasma values of elastase 
rose gradually during cardiopulmonary bypass in 
both groups (Fig. 4). The peak levels occurred after 
the end of cardiopulmonary bypass, with signifi- 
cantly higher levels in the leukocyte filter group (460 
/xg/L in leukocyte filter group versus 230 /xg/L in 
control group, 95% confidence interval, 101 to 359 
txg/L, p = 0.003; laboratory reference range 2 to 42 
/×g/L). The fast decrease of the elastase values was 
observed after the end of cardiopulmonary b pass. 
Six hours after the operation the elastase levels were 
just moderately higher than the baseline values. 
Assessment of postoperative lung function. 
There was no difference in intubation time between 
the groups (16.2 hours for leukocyte filter group 
versus 15.6 hours for control group, 95% confidence 
interval, 12.1 to 19.1 hours,/) = 0.72). The time 
course of oxygenation i dex (arterial oxygen ten- 
sion/inspired oxygen fraction) values for both 
groups is shown in Fig. 5. The calculation of area 
under the curve revealed no statistically significant 
difference between the groups (290 area under the 
curve for oxygenation i dex of leukocyte-depleted 
group versus 329 area under the curve for oxygen- 
ation index of control group, 95% confidence inter- 
val, 286 to 372,p = 0.21). The regression coefficient 
of oxygenation index versus logarithm of elastase 
values (R 2 = 0.20) was statistically significant (p = 
0.016) but clinically irrelevant, indicating that just 
20% of variations of oxygenation index could be 
explained through the changes in elastase values. 
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Fig. 1. Total white blood cell counts (mean +_ standard error of mean). L, Leukocyte filter group; C, 
control group; CPB, cardiopulmonary b pass. 
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Fig. 2. Time course of neutrophil counts (mean _+ standard error of mean). L, Leukocyte filter group; C, 
control group; CPB, cardiopulmonary b pass. 
The postoperative pulmonary vascular resistance 
values did not differ between the leukocyte filter and 
control groups (p = 0.10; Fig. 6). The dosage of 
vasodilators administered in the same period was 
similar in both groups (leukocyte filter versus con- 
trol: phentolamine, 150 _+ 19/xg/min versus 228:2 
67/xg/min, p = 0.41; nitroglycerin, 75 _+ 13 ~g/min 
versus 89 _+ 15 ~g/min, p = 0.48). 
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Fig. 3. Lymphocyte counts (mean _+ standard error of mean). L, Leukocyte filter group; C, control group; 
CPB, cardiopulmonary b pass. 
Discussion 
The use of a leukocyte-depleting filter for extra- 
corporeal circulation did not cause a significant 
reduction in the number of circulating leukocytes 
during cardiopulmonary b pass. There was no im- 
provement of postoperative lung function in the 
leukocyte filter group as assessed by oxygenation 
index, pulmonary vascular resistance, and intubation 
time. The higher plasma levels of elastase that 
occurred as a consequence of leukocyte filtration 
did not significantly influence the lung function 
parameters measured in this study. 
Accumulated knowledge regarding the mecha- 
nism of neutrophil-mediated lung dysfunction after 
bypass has led to several unspecific pharmacologic 
interventions directed toward the inhibition of gran- 
ulocyte activation and aggregation. Administration 
of anisodamine (M-cholinergic receptor blocker) 
reduced pulmonary granulocyte sequestration and 
lung water content after cardiopulmonary b pass in a 
canine experimental model. 14 Treatment with nifedip- 
ine and deferoxamine in clinical trials resulted in 
partial inhibition of granulocyte activation during car- 
diopulmonary b pass, even in the presence of comple- 
ment activation. 15' 16 However, the potential clinical 
benefit of those treatments was not documented. 
The experimental use of leukocyte filtration 
posed an attractive alternative to the pharmacologic 
interventions. The reduction in the number of cir- 
culating leukocytes preserved arterial oxygenation, 
minimized pulmonary leukocyte sequestration, and 
prevented postoperative changes in pulmonary vas- 
cqlar resistance in a canine model. 1° The protective 
effects of leukocyte depletion on postoperative lung 
function were demonstrated in a bovine model of 
heart-lung transplantation aswell. TM 12 
The efficacy of the new leukocyte-depleting arte- 
rial blood filter for extracorporeal service (Leuko- 
Guard-6) was documented in an experimental set- 
ting with the use of fresh heparinized bovine blood 
perfusate. 17The leukocytes present in the small vol- 
ume of bovine blood (1100 ml) were efficiently filtered 
after several passes through the filter during 90 min- 
utes of recirculation at high flow rates (4.5 L/min). 
However, such an experimental design does not en- 
tirely simulate clinical conditions. The analysis of leu- 
kocyte dynamics in our study showed increased mobi- 
lization of leukocytes during the last phase of 
cardiopulmonary b pass, which corresponds with the 
data from previous tudies. 6' 18-20 The separate analysis 
of neutrophil and lymphocyte counts showed that 
postoperative leukocytosis i  the consequence of neu- 
trophilia, which may be the result of enhanced mobi- 
lization of granulocytes from the marginated pool or 
release of new cells from the bone marrow. The 
discrepancy between the neutrophil depletion rate of 
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Fig. 4. Plasma elastase values (mean _+ standard error of mean). L, Leukocyte filter group; C, control 
group; CPB, cardiopulmonary bypass; asterisk, p = 0.003. 
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Fig. 5. Oxygenation index (mean ± standard error of mean) for leukocyte filter (L) and control group (C). 
70% observed in the experimental setting and the 
failure of the filter in the clinical trial could be ex- 
plained through the additional load of newly mobilized 
cells, which exceeded the capacity of the filter. 
Elastase is a major constituent of azurophilic gran- 
tries of human polymorphonuclear leukocytes and can 
be used as a specific marker of granulocyte activa- 
tion.aS, 18 Elevated plasma levels of elastase during 
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Fig. 6. Pulmonary vascular esistance (PVR). L, Leukocyte filter group; C, control group; CPB, cardio- 
pulmonary bypass. 
cardiopulmonary b pass reflect neutrophil injury or 
activation and positively correlate with the duration of 
extracorporeal circulation. 21 In the current study the 
elevated elastase levels in the leukocyte filter group 
could be considered as a side effect of filtration caused 
by the activation of neutrophils after the contact with 
the nonwoven polyester fiber surface of the filter. 
The capacity of neutrophils to damage ndothe- 
lial cells and cause lung injury has been noted both 
in vitro and in vivo, and neutrophil elastase has been 
implicated in this endothelial cytotoxicity. 22' 23 The 
correlation between elastase levels and the oxygen- 
ation index in the current study was statistically 
significant, but not clinically relevant, indicating that 
just 20% of variations of oxygenation i dex can be 
explained through the changes in elastase levels. 
This finding correlates well with those of recent 
clinical studies and indicates a multifactorial origin 
of pulmonary dysfunction after cardiopulmonary 
bypass. 21 Furthermore, there was no obvious clinical 
consequence r garding intubation time, which did 
not differ between the groups. 
Cell death is not the obligatory outcome of elas- 
tase-endothelial cell interaction. In vitro studies 
with lower concentrations of elastase revealed its 
reversible effect on endothelial prostaglandin 12 
production in response to extracellular adenosine 
triphosphate, which suggests the vasoregulatory 
properties of this protease. 24 The reduction in pul- 
monary vascular esistance in patients after esoph- 
ageal cancer operations after infusions of the neu- 
trophil elastase inhibitor ulinastatin indicated the 
clinical importance of experimental observations. 25 
We were not able to demonstrate any measurable 
effect of higher elastase concentrations in the leu- 
k0cyte filter group on pulmonary vascular resis- 
tance, which indicates low clinical relevance of in 
vitro findings. 
The clinical use of a leukocyte filter has not 
fulfilled the expectations suggested by the results 
from experimental studies. The assessment of vari- 
ous aspects of lung function (oxygenation index, 
pulmonary vascular esistance, and intubation time) 
did not show any improvement in these aspects in 
the leukocyte filter group. The question of whether 
the release of elastase as a consequence of neutro- 
phil filtration poses a real danger to the lungs 
remains open. Even a slight degree of filtration, such 
as presumably occurred in our study, resulted in the 
large increase in elastase plasma concentration. It 
could be easily postulated that more efficient me- 
chanical filtration would induce even higher elastase 
peaks. On the other hand, the high degree of 
leukocyte depletion resulted in excellent postopera- 
tive lung function in the experimental setting. Un- 
fortunately, elastase l vels were not measured in any 
of these studiesJ °-12 
The future development of leukocyte filters with 
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higher capacity could provide the definite answer 
considering clinical benefits associated with leuko- 
cyte depletion. Further studies are necessary to 
prove whether the elevation of elastase levels could 
be reduced by the selective use of the filter just 
before the reperfusion of the lungs. 
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